Biomedical subjects

Chang Zhu

Publications and source records attributed to Chang Zhu.

5 recordsLinked to original sources

PubMed2005

[The clinic analysis of complications of varied breast implant].

OBJECTIVE: The study was carried out through summarizing and comparing the percentages of long-term complications of four types breast implants, and analyzing the cause of complications. METHODS: The study reviewed 573 patients with breast implants including textured or smooth silicone gel-filled or saline filled implants which were placed between 1993 and 2002. 427 cases were selected to followed-up in which the surgical technique, the plane of placement and the operator were all the same. Basing on outcomes of following-up, we summarized all kinds of long-term complications and the incidence of every type of implant. RESULTS: There were 803 of 832 prostheses (94.24%) with good results in 427 cases, while 49 prostheses (5.76%) with varied complications in 42 cases. Baker level III or IV contracture occurred in 26 prostheses, reduction of the breast in 24 prostheses, malposition or pain in 10 prostheses. Rupture or leakage were detected in repeated surgery in 24 prostheses. The more severe capsular contracture happened in cases with silicone gel-filled implant than in cases with saline-filled implant. The reduction of the breast due to the rupture or leakage of implants almost occurred in cases with saline-filled implants. The study also implied the complication incidence had the positive correlation with the length of time after implantation. CONCLUSIONS: The data provided by the statistic analysis demonstrated that the distinctly difference of the complication incidence exist only between smooth saline-filled implants and smooth silicone gel-filled implants. But there were no difference among the others. In 30 of 49 prostheses with varied complication of rupture or leakage were detected which could cause the other severe complication. So the quality of implants is the key to decrease the complication incidence, then the degeneration of prostheses after being implanted becomes the urgent and troublesome problem to solve for all of us.

Adolescent↗

PubMed2003

Adenosine kinase inhibitors: polar 7-substitutent of pyridopyrimidine derivatives improving their locomotor selectivity.

We have discovered that polar 7-substituents of pyridopyrimidine derivatives affect not only whole cell AK inhibitory potency, but also selectivity in causing locomotor side effects in vivo animal models. We have identified compound, 1o, which has potent whole cell AK inhibitory potency, analgesic activity and minimal reduction of locomotor activity.

Adenosine Kinase↗

PubMed2003

[Analysis of the Millard method for unilateral cleft lip repair].

OBJECTIVE: To analyze and describe the advantages and disadvantages of the Millard repair in the unilateral cleft lip (UCL). METHODS: In 30 patients with UCL undergoing the cleft lip repair with the Millard I or II method, the vermilion was repaired by a modified method with a triangle flap, while the alar cartilage reposition was performed. RESULTS: Postoperative follow-up of 6-12 months revealed the good results with invisible scar, good preservation of philtrum dimple and column, full vermilion and lengthened columella, good alar cartilage reposition. CONCLUSION: The Millard method is good for UCL repair. The modified technique with a triangle flap on the vermilion edge can overcome Millard's disadvantages. The anatomic reposition of the affected alar cartilage by blunt dissection at the first stage is suitable for the oriental.

Adolescent↗

PubMed2002

Analgesic and anti-inflammatory effects of A-286501, a novel orally active adenosine kinase inhibitor.

Adenosine (ADO) is an inhibitory neuromodulator that can increase nociceptive thresholds in response to noxious stimulation. Inhibition of the ADO-metabolizing enzyme, adenosine kinase (AK) increases extracellular ADO concentrations at sites of tissue trauma and AK inhibitors may have therapeutic potential as analgesic and anti-inflammatory agents. N7-((1'R,2'S,3'R,4'S)-2',3'-dihydroxy-4'-amino-cyclopentyl)-4-amino-5-bromo-pyrrolo[2,3-a]pyrimidine (A-286501) is a novel and potent (IC50=0.47 nM) carbocyclic nucleoside AK inhibitor that has no significant activity (IC50 >100 microM) at other sites of ADO interaction (A1, A2A, A3 receptors, ADO transporter, and ADO deaminase) or other (IC50 value >10 microM) neurotransmitter and peptide receptors, ion channel proteins, neurotransmitter reuptake sites and enzymes, including cyclooxygenases-1 and -2. A-286501 showed equivalent potency to inhibit AK from several mammalian species and kinetic studies revealed that A-286501 was a reversible and competitive inhibitor with respect to ADO and non-competitive with respect to MgATP2-. A-286501 was orally effective to reduce nociception in animal models of acute (thermal), inflammatory (formalin and carrageenan), and neuropathic (L5/L6 nerve ligation and streptozotocin-induced diabetic) pain. A-286501 was particularly potent (ED50=1 micromol/kg, p.o.) to reduce carrageenan-induced inflammatory thermal hyperalgesia as compared to its analgesic actions in other pain models (acute and neuropathic) and its ability to alter hemodynamic function and motor performance. A-286501 was also effective to reduce carrageenan-induced paw edema and myeloperoxidase activity, a measure of neutrophil influx (ED50=10 micromol/kg, p.o.), in the injured paw. The anti-nociceptive effects of A-286501 in the L5/L6 nerve injury model of neuropathic pain (ED50=20 micromol/kg, p.o.) were not blocked by the opioid antagonist naloxone, but were blocked by the ADO receptor antagonist, theophylline. Following repeated administration, A-286501 showed less potential to produce tolerance as compared to morphine. Thus, A-286501 is a structurally novel AK inhibitor that effectively attenuates nociception by a non-opioid, non-non-steroidal anti-inflammatory drug ADO, receptor mediated mechanism.

Adenosine Kinase↗

PubMedDate not supplied

Endoscopic transaxillary capsulectomy.

BACKGROUND: Traditionally, breast implant extraction and capsulectomy have been performed using a transareolar approach. However, this approach is not acceptable to Chinese patients because of the additional scar formation. The authors present their experience with capsulectomy using transaxillary endoscopic assistance without the need for an additional incision. METHODS: The former transaxillary incisional scar for augmentation mammoplasty is used. Blunt dissection is performed to the outer surface of the fibrous capsule. A 30 degrees , 10-mm endoscope is placed through the axillary incision to dissect the outer surface of the capsule. After this is finished, the capsule is cauterized open, and extraction is completed. Transaxillary capsulectomy is performed under endoscopic control. RESULTS: From 2003 to 2005, a total of 30 breasts involving 15 patients were treated. The follow-up period was 4 to 6 months, with favorable results. No scar was left on the breast, and no additional scar was made. No liquid accumulation was identified. CONCLUSIONS: Endoscopic transaxillary capsulectomy can be completed through the axillary incision. The technique successfully removed the fibrous capsule, eliminated the needed for an incision on the breast, and created an incision far from the breast for completion of the procedure.

Adult↗